

[View this email in your browser](#)

Liver Digest

A weekly update of PLRC happenings

January 2, 2020



**PITTSBURGH LIVER
RESEARCH CENTER**

A partnership of University of Pittsburgh & UPMC

www.livercenter.pitt.edu

Featured Faculty - Dr. Hun-Way Hwang

In this issue

- [Next Week's Seminars](#)
- [Faculty Highlights](#)
- [Spring Liver Conferences](#)



PLRC SIG

PLRC Tumorigenesis SIG

Tue, 1/7/2020

12:00 to 1:00 pm

S123 BST

Dr. Michael Nalesnik - Molecular Classification of HCC

Dr. Silvia Liu - Novel Biomarker Discovery in HCC

Pizza will be provided.

The full schedule of Enrichment activities is posted on <https://www.livercenter.pitt.edu/events>.

Faculty Highlights

PLRC members collaborating on manuscripts are noted in red.

Original Article: Trivedi N, Weisel F, Smita S, Joachim S, Kader M, Radhakrishnan A, Clouser C, Rosenfeld AM, **Chikina M**, Vigneault F, Hershberg U, Ismail N, Shlomchik MJ. Liver Is a Generative Site for the B Cell Response to Ehrlichia muris. Immunity. 2019 Nov 9. pii: S1074-7613(19)30448-0. doi: 10.1016/j.immuni.2019.10.004. PubMed PMID: 31732168.

ABSTRACT

The B cell response to Ehrlichia muris is dominated by plasmablasts (PBs), with few-if any-germinal centers (GCs), yet it generates protective immunoglobulin M (IgM) memory B cells (MBCs) that express the transcription factor T-bet and harbor V-region mutations. Because Ehrlichia prominently infects the liver, we investigated the nature of liver B cell response and that of the spleen. B cells within infected livers proliferated and underwent somatic hypermutation (SHM). Vh-region sequencing revealed trafficking of clones between the spleen and liver and often subsequent local clonal expansion and intraparenchymal localization of T-bet+ MBCs. T-bet+ MBCs expressed MBC subset markers CD80 and PD-L2. Many T-bet+ MBCs lacked CD11b or CD11c expression but had marginal zone (MZ) B cell phenotypes and colonized the splenic MZ,

revealing T-bet+ MBC plasticity. Hence, liver and spleen are generative sites of B cell responses, and they include V-region mutation and result in liver MBC localization.

For full text, please [click here](#).

Original Article:

Beard RE, Khan S, Troisi RI, Montalti R, Vanlander A, Fong Y, Kingham TP, Boerner T, Berber E, Kahramangil B, Buell JF, Martinie JB, Vrochides D, Shen C, Molinari M, **Geller DA**, Tsung A. Long-Term and Oncologic Outcomes of Robotic Versus Laparoscopic Liver Resection for Metastatic Colorectal Cancer: A Multicenter, Propensity Score Matching Analysis. *World J Surg*. 2019 Nov 20. doi: 10.1007/s00268-019-05270-x. PubMed PMID: 31748885.

ABSTRACT

BACKGROUND: To assess long-term oncologic outcomes of robotic-assisted liver resection (RLR) for colorectal cancer (CRC) metastases as compared to a propensity-matched cohort of laparoscopic liver resections (LLR). Although safety and short-term outcomes of RLR have been described and previously compared to LLR, long-term and oncologic data are lacking.

METHODS: A retrospective study was performed of all patients who underwent RLR and LLR for CRC metastases at six high-volume centers in the USA and Europe between 2002 and 2017. Propensity matching was used to match baseline characteristics between the two groups. Data were analyzed with a focus on postoperative and oncologic outcomes, as well as long-term recurrence and survival.

RESULTS: RLR was performed in 115 patients, and 514 patients underwent LLR. Following propensity matching 115 patients in each cohort were compared. Perioperative outcomes including mortality,

morbidity, reoperation, readmission, intensive care requirement, length-of-stay and margin status were not statistically different. Both prematching and postmatching analyses demonstrated similar overall survival (OS) and disease-free survival (DFS) between RLR and LLR at 5 years (61 vs. 60% OS, $p=0.87$, and 38 vs. 31% DFS, $p=0.25$, prematching; 61 vs. 60% OS, $p=0.78$, and 38 vs. 44% DFS, $p=0.62$, postmatching).

CONCLUSIONS: Propensity score matching with a large, multicenter database demonstrates that RLR for colorectal metastases is feasible and safe, with perioperative and long-term oncologic outcomes and survival that are largely comparable to LLR.

For full text, please [click here](#).

Upcoming Liver Conferences

35th Annual New Treatments in Chronic Liver Disease

March 20-22, 2020

Hilton San Diego Resort, San Diego, California

[Click here to visit website](#)

GI and Liver Association of the Americas

7th Annual Dallas Conference

March 20-21, 2020

Arlington, Texas

[Click here to visit website](#)

AASLD-EASL NAFLD and NASH Clinical Endpoints Conference

March 21-22, 2020

Topic: Metabolism, alcohol and toxicity

The Westin Crystal City, 1800 Jefferson Davis Hwy, Arlington, VA
22202 | Washington D.C., United States

[Click here to visit website](#)

Mayo Clinic Gastroenterology & Hepatology 2020

March 26 - 29, 2020

Amelia Island, Florida

[Click here to visit website](#)

4th Annual NASH Summit 2020

May 4 - 6, 2020

Boston, Massachusetts

[Click here to visit website](#)



Copyright © 2019 Pittsburgh Liver Research Center, All rights reserved.

Our mailing address is:

Pittsburgh Liver Research Center
200 Lothrop St. | Pittsburgh, PA 15261